Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis.
Objective:
The aim of our study was to evaluate the scientific evidence for the efficacy and safety of biologic drugs for psoriasis.
Methods:
The studies reviewed include data on the biologies alefacept, efalizumab, etanercept, and infliximab. This article reviews all data published in the dermatology literature listed in the MEDLINE database, as well as data presented as abstracts and posters at dermatology society meetings, including the annual meetings of the American Academy of Dermatology.
Results:
The majority of the studies used an improvement from baseline of 75% or more in the psoriasis area and severity index (PASI 75) as the primary measure of efficacy.
Conclusions:
Overall, biologics represent an important addition to the psoriatic therapies and have a great impact on the disease course and life quality of those afflicted with psoriasis.
Get full access to this article
View all access options for this article.
References
1.
KooJ. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin1996; 14:485–196.
2.
National Psoriasis Foundation. About psoriasis: FAQs [online article]. Available at: http://www.psoriasis.org/b500.htm; accessed July 11, 2003.
3.
CDCP. Vital and health statistics: Current estimates from the National Health Interview Survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics. 2003.
4.
KruegerGKooJLebwohlM. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol2001; 137:280–284.
5.
BarankinBDeKovenJ. Psychosocial effect of common skin diseases. Can Fam2001; 48:712–716.
6.
VoorheesJJ. Dohi Memorial Lecture: Psoriasis—an immunological disease. J Dermatol1996; 23:851–857.
7.
PartschGSteinerGLeebBF. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol1997; 24:518–523.
8.
DanningCLIlleiGGHitchonC. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum2000; 43:1244–1256.
9.
GreavesMWWeinsteinGD. Treatment of psoriasis. N Engl J Med1995; 332:581–588.
10.
CamisaC. Psoriasis: A clinical update on diagnosis and new therapies. Cleve Clin J Med2000; 67:105–113, 117.
11.
GuentherL. Tazarotene combination treatments in psoriasis. J Am Acad Dermatol2000; 43:S36–S42.
12.
GordonPMDiffeyBLMatthewsJNFairPM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol1999; 41:728–732.
13.
BehrensSGrundmann-KollmannMSchienerR. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol2000; 42:493–495.
14.
WitmanPM. Topical therapies for localized psoriasis. Mayo Clin Proc2001; 76:943–949.
Alefacept(Amevive) for treatment of psoriasis. Med Lett Drugs Ther2003; 45:31–32.
20.
OrtonneJP. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Verereol2003; 17(Suppl 2):12–16.
21.
LebwohlMChristophersELangleyR. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol2003; 139:719–727.
22.
KruegerGGPappKAStoughDB. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol2002; 47:821–833.
23.
MarzellaLPapadopoulosEWangC. PDA Final Clinical Review: Biologic License Application STN BL 125036/0 for alefacept for treatment of moderate to sever chronic plaque psoriasis, submitted April 29, 2002.
24.
GottliebABBlackerKDuvicM. Efficacy and safety of efalizumab long term treatment: Preliminary findings from an open label trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 11.
25.
GottliebABGordonKBKooJY. Long-term efalizumab treatment maintains clinical benefit in patients with moderate to severe plaque psoriasis: Updated findings from an open-label trial [abstract]. Presented at the Annual Meeting of the American Academy of Dermatology, 25–29 July 2003, Chicago, Illinois, poster 43.
26.
SingriPWestDPGordonKB. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol2002; 138:657–663.
27.
PDA Advisory Committee. Genentech/Xoma Raptiva potential use as second-line psoriasis therapy to be discussed by committee [press release], September 8, 2003.
28.
PapadopoulosEMarzellaL. FDA Briefing Document: Biologic License Application STN BL 125075/0 for efalizumab for the treatment of moderate to severe chronic plaque psoriasis, submitted December 27, 2002.
29.
GordonKBTyringSKHamiltonTK. Examining duration of response and rebound during treatment with efalizumab (anti-CD 11a) [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 594.
30.
MeasePJGoffeBSMetzJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet2000; 356:385–390.
31.
GottliebABLoweNJMathesonRT. Efficacy of etanercept in patients with psoriasis [abstract]. Presented at the 60th Annual Spring 2003 Meeting of the American Academy of Dermatology, 22–27 February 2002, New Orleans, Louisiana.
32.
PappKZitnikR. Efficacy and safety of etanercept in patients with psoriasis: Results of a global 12 week phase III study [abstract]. Workshop presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New York.
33.
LeonardiCGottliebAB, Zitnik R, for the Etanercept Psoriasis Study Group. Efficacy and safety of etanercept in patients with psoriasis: Results of a phase 3 study [abstract]. Presented at the International Investigative Dermatology Annual Meetings, 30 April–4 May 2003, Miami Beach, Florida, poster 0409.
34.
LeonardiCLPowereJLMathesonRT. Etanercept as monotherapy in patients with psoriasis. N Engl J Med2003; 349:2014–2022.
35.
ChaudhariURomanoPMulcahyLD. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet2001; 357:1842–1847.
36.
GottliebABLiSEvansR. Infliximab in the treatment of psoriasis: Results from the first 10 weeks of the phase II trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 596.
37.
GottliebABEvansRLiS. The efficacy and safety of infliximab induction therapy in patients with moderate to svere plaque-type psoriasis [abstract]. Poster presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New York.
